Titre:
  • Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Auteur:Van Cutsem, Eric; Li, C. P.; Nowara, Elzbieta; Aprile, G; Moore, Malcolm J; Federowicz, I; Van Laethem, Jean-Luc; Hsu, C; Tham, C K; Stemmer, S M; Lipp, R; Zeaiter, A; Fittipaldo, A; Csutor, Z; Klughammer, B; Meng, X; Ciuleanu, T
Informations sur la publication:British Journal of Cancer, 111, 11, page (2067-2075)
Statut de publication:Publié, 2014-11
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:dose
epidermal growth factor
erlotinib
oncology
pancreatic cancer
rash
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0007-0920
info:doi/10.1038/bjc.2014.494
info:pii/bjc2014494
info:scp/84927176540
info:pmid/25247318
PMC4260026